Explore / Clinical trial
Clinical trial

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Sheppard Pratt Health SystemUnknownPhase 2Started Mar 1, 202115 enrolledUnited StatesNCT04433845

Abstract

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

Treatment Resistant Depression
View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticlePsilocybin

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.

Aaronson ST, van der Vaart A, Miller T +6

Europe PMC2024

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022
ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023
ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5

Europe PMC2022